• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pulmonology

The PAGE trial: clinical outcomes do not improve with inhaled GM-CSF in pulmonary alveolar proteinosis patients

byDayton McMillan
September 11, 2019
in Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with pulmonary alveolar proteinosis, use of twice daily inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) did not improve clinical outcomes of vital capacity or functional walk test compared to placebo treated patients.

2. Laboratory and imaging metrics suggestive of reduced pulmonary disease were noted in GM-CSF treated patients.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Accumulation of surfactant within pulmonary alveoli, often due to autoimmunity against GM-CSF, is the pathologic finding observed in patients with pulmonary alveolar proteinosis. The present treatment to reduce surfactant is lung lavage which is invasive and requires repeated procedures. Preclinical and early clinical studies have shown inhaled GM-CSF can break down surfactant and improve gas exchange, though the efficacy of treatment in patients with mild-to-moderate disease is unknown. The Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy (PAGE) trial randomized patients to receive inhaled GM-CSF or placebo over 24 weeks. The primary outcome of change in alveolar-arterial (AA) gradient between baseline and week 25 showed a significant improvement in the treatment group. Additionally, reduced pulmonary intensity characteristic of reduced fluid was seen in treated patients. Clinical metrics including patient-reported disease outcomes, vital capacity, and functional walk testing were similar in the treatment and placebo groups.

This randomized trial suggests inhaled GM-CSF is improving physiologic gas exchange in pulmonary alveolar proteinosis patient lungs. Validation of clinical efficacy may require longer follow-up, alternate dosing, or study in patients with a different disease severity.

Click to read the study in NEJM

Relevant Reading: Prevalence and healthcare burden of pulmonary alveolar proteinosis

RELATED REPORTS

Lung recruitment improves efficacy of surfactant treatment in extremely preterm neonates

#VisualAbstract: Inhaled GM-CSF for Pulmonary Alveolar Proteinosis

Artificial surfactant linked to significant improvement of RDS [Pediatrics Classics Series]

In-Depth [randomized controlled trial]: This multicenter, randomized, placebo-controlled study enrolled patients in 2016. Eligible adult patients had a diagnosis of autoimmune pulmonary alveolar proteinosis, clinical symptoms of pulmonary disease, and a reduced partial pressure of oxygen. Patients who had a recent lung lavage procedure, had previously received GM-CSF, or had markedly decreased oxygenation measurements were excluded. Patients were randomized to receive 125 μg of GM-CSF twice daily (n=33), with alternating weeks of taking the treatment or not, or a placebo for a total intervention period of 24 weeks (n=30). The primary endpoint of change from baseline in AA gradient at 25 weeks was improved in the GM-CSF group compared to placebo patients (mean change from baseline, −4.50 mmHg vs. 0.17 mmHg; P=0.02). Similarly, a higher partial pressure of oxygen was observed in the treatment group (4.77mm Hg vs. -0.05 mmHg for placebo; difference vs. placebo, 5.40; 95% confidence interval [CI], 1.00 to 9.90). Pulmonary computed tomography imaging showed significantly decreased image intensity in treated patients after 24 weeks, suggesting reduced pulmonary fluid characteristic of disease pathology. Patient reported pulmonary disease severity scores, dyspnea scores, and functional walking test metrics did not differ between treated and placebo patients. In subgroup analysis of smokers, AA gradients were not significantly affected with GM-CSF treatment. Occurrence of adverse events was similar between treated and placebo patients.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: autoimmune pulmonary alveolar proteinosisgranulocyte-macrophage colony-stimulating factor (GM-CSF)surfactant
Previous Post

#VisualAbstract: Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES)

Next Post

The CLASS trial: laser ablation and surgery improve quality-of-life for varicose vein patients compared to sclerotherapy

RelatedReports

Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial
Obstetrics

Lung recruitment improves efficacy of surfactant treatment in extremely preterm neonates

August 3, 2020
#VisualAbstract: Inhaled GM-CSF for Pulmonary Alveolar Proteinosis
StudyGraphics

#VisualAbstract: Inhaled GM-CSF for Pulmonary Alveolar Proteinosis

October 2, 2019
Pediatrics

Artificial surfactant linked to significant improvement of RDS [Pediatrics Classics Series]

August 14, 2014
Obtaining consent for c-section during labor may be suboptimal
Obstetrics

Adjusted neonatal care coincides with decreased morbidity and mortality

July 16, 2013
Next Post
The CLASS trial: laser ablation and surgery improve quality-of-life for varicose vein patients compared to sclerotherapy

The CLASS trial: laser ablation and surgery improve quality-of-life for varicose vein patients compared to sclerotherapy

#VisualAbstract: Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

#VisualAbstract: Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer

Diet and physical activity promotion associated with decreased risk of type 2 diabetes

Quick Take: HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Newborn screening for cystic fibrosis improves nutritional outcomes
  • BNT162b2 vaccine reduces rates of COVID-19 omicron variant infection in children
  • Non-contrast CT sensitive and specific for kidney stones [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.